Advertisement

Clinical and Translational Oncology

, Volume 19, Issue 1, pp 105–110 | Cite as

CT scan prior to radiotherapy in unresectable, locally advanced, non-small cell carcinoma of the lung: is it always necessary?

  • D. Calvo TempranoEmail author
  • E. Esteban
  • P. Jiménez Fonseca
  • B. Fernández-Mariño
Research Article
  • 122 Downloads

Abstract

Purpose

There is broad consensus regarding evaluating response to chemotherapy (CHT) by means of computerized tomography (CT) in patients with localized or locally advanced non-small cell lung carcinoma (NSCLC). We present a study comparing the usefulness of CT versus chest X-ray (XR) and clinical findings when indicating radiotherapy (RT) following CHT.

Methods

Ninety-eight of 150 subjects with unresectable locally advanced NSCLC were blindly and independently evaluated by XR and CT, with pairs of chest XR and CT (before and after CHT). A null hypothesis (H0) was established of the conditioned probability of detecting progression by CT and not by XR of 10 % or more, with a statistical power of 80 %.

Results

Sensitivity, specificity, positive and negative predictive value of XR versus CT were 98, 89, 99, and 80 % respectively. A 4 % (p = 0.0451) probability of improvement of CT versus XR was calculated, enabling the H0 to be ruled out.

Conclusion

The CT failed to prove to be significantly superior to the chest XR + clinical picture in indicating a change in treatment approach in patients with unresectable locally advanced NSCLC after CHT.

Keywords

Non-small cell carcinoma of the lung Lung cancer Lung cancer staging Chest X-ray Computerized tomography RECIST 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The current study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All persons gave their informed consent prior to their inclusion in the study.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Tsao AS, Scagliotti GV, Bunn PA Jr, Carbone DP, Warren GW, Bai C, et al. Scientific advances in lung cancer 2015. J Thorac Oncol. 2016 (p ii: S1556-0864(16)30022-3, Epub ahead of print ).Google Scholar
  2. 2.
    Redmond KL, Papafili A, Lawler M, Van Schaeybroeck S. Overcoming resistance to targeted therapies in cancer. Semin Oncol. 2015;42:896–908.CrossRefPubMedGoogle Scholar
  3. 3.
    Goldstein DA, Zeichner SB, Bartnik CM, Neustadter E, Flowers CR. Metastatic colorectal cancer: a systematic review of the value of current therapies. Clin Colorectal Cancer. 2016;15:1–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Winn AN, Ekwueme DU, Guy GP Jr, Neumann PJ. Cost-utility analysis of cancer prevention, treatment, and control: a systematic review. Am J Prev Med. 2016;50:241–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Garrido P, de Castro J, Concha Á, Felip E, Isla D, López-Ríos F, et al. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Transl Oncol. 2012;14:338–49.CrossRefPubMedGoogle Scholar
  6. 6.
    Jassem J. The role of radiotherapy in lung cancer: where is the evidence? Radiother Oncol. 2007;83:203–13.CrossRefPubMedGoogle Scholar
  7. 7.
    Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. LACE Collaborative Group. Lung adjuvant cisplatin evaluation; a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II and IIIA NSCLC. J Clin Oncol. 2002;20:247–53.CrossRefPubMedGoogle Scholar
  9. 9.
    Quint LE, Francis IR, Wahl RL, Gross BH, Glazer GM. Preoperative staging of non-small-cell carcinoma of the lung: imaging methods. AJR Am J Roentgenol. 1995;164:1349–59.CrossRefPubMedGoogle Scholar
  10. 10.
    Schimmer C, Neukam K, Elert O. Staging of non-small cell lung cancer: clinical value of positron emission tomography and mediastinoscopy. Interact CardioVasc Thorac Surg. 2006;5:418–23.CrossRefPubMedGoogle Scholar
  11. 11.
    Hochhegger B, Alves GR, Irion KL, Fritscher CC, Fritscher LG, Concatto NH, et al. PET/CT imaging in lung cancer: indications and findings. J Bras Pneumol. 2015;41:264–74.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, et al. ASCO treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2004;22:330–53.CrossRefPubMedGoogle Scholar
  13. 13.
    Edge SB, Byrd DR, Compton CC. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.Google Scholar
  14. 14.
    Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. Am Fam Phys. 2007;75:56–63.CrossRefGoogle Scholar
  15. 15.
    Cadranel J, Lavolé A, Gounant V, Wislez M. Clinical types of thoracic cancer. Bronchiolo-alveolar carcinoma and adenocarcinoma with bronchioloalveolar features: a clinico-pathological spectrum. Rev Mal Respir. 2006;23:16S158–63.CrossRefPubMedGoogle Scholar
  16. 16.
    Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition. J Thorac Oncol. 2008;3:457–66.CrossRefPubMedGoogle Scholar
  17. 17.
    Albain KS, Swann RS, Rusch VW, Turrisi AT, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379–86.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181–90.CrossRefPubMedGoogle Scholar
  19. 19.
    O’Rourke N, Roqué I, Figuls M, Farré Bernadó N, Macbeth F. Concurrent chemoradiotherapy in non-small-cell lung cancer. Cochrane Database Syst Rev. 2010:cd002140.Google Scholar
  20. 20.
    Gandara DR, Aberle D, Lau D, Jett J, Akhurst T, Heelan R, et al. Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol. 2006;1:S20–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Esteban E, De Sande JL, Villanueva N, Corral N, Muñiz I, Vieitez JM, et al. Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomised study. E. Lung Cancer. 2007;55:173–80.CrossRefGoogle Scholar
  22. 22.
    European guidelines on quality criteria for diagnostic radiographic images. Report EUR 16260. 1996.Google Scholar
  23. 23.
    Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst. 2000;92:205–16.CrossRefPubMedGoogle Scholar
  24. 24.
    Shao J, editor. Mathematical statistics. New York: Springer; 2003.Google Scholar
  25. 25.
    Shao J, Tu D, editors. The jackknife and bootstrap. New York: Springer; 1995.Google Scholar
  26. 26.
    Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990;323:940–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Le Chevalier T, Arriagada R, Quoix E, Ruffie P, de Cremoux H, Douillard JY, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small-cell lung carcinoma: first analysis of to randomized trial in 353 patients. J Natl Cancer Inst. 1991;83:417–23.CrossRefPubMedGoogle Scholar
  28. 28.
    Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb non-small-cell lung cancer. A meta-analysis. Cancer. 1995;7:593.CrossRefGoogle Scholar
  29. 29.
    Stamatis G. Staging of lung cancer: the role of noninvasive, minimally invasive and invasive techniques. Eur Respir J. 2015;46(2):521–31.CrossRefPubMedGoogle Scholar
  30. 30.
    Bonnette P. Chemo-radiotherapy before surgery in stage III non-small-cell lung cancer. Rev Mal Respir. 2013;30(2):105–14.CrossRefPubMedGoogle Scholar
  31. 31.
    Johnson DH, Schiller JH, Bunn PA Jr. Recent clinical advances in lung cancer management. J Clin Oncol. 2014;32(10):973–82.CrossRefPubMedGoogle Scholar
  32. 32.
    Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: west Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol. 2010;28(23):3739–45.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2016

Authors and Affiliations

  • D. Calvo Temprano
    • 1
    Email author
  • E. Esteban
    • 2
  • P. Jiménez Fonseca
    • 2
  • B. Fernández-Mariño
    • 1
  1. 1.Radiology ServiceHospital Universitario Central de AsturiasOviedoSpain
  2. 2.Medical Oncology ServiceHospital Universitario Central de AsturiasOviedoSpain

Personalised recommendations